Vaccitech Stock Forecast, Price & News

Vaccitech (NASDAQ:VACC) Frequently Asked Questions

Is Vaccitech a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vaccitech stock.
View analyst ratings for Vaccitech or view top-rated stocks.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.25. The business earned $0.02 million during the quarter, compared to analyst estimates of $1.65 million. Vaccitech had a negative trailing twelve-month return on equity of 38.44% and a negative net margin of 7,428.78%.
View Vaccitech's earnings history.

What price target have analysts set for VACC?

4 equities research analysts have issued 1-year price targets for Vaccitech's shares. Their forecasts range from $22.00 to $28.00. On average, they expect Vaccitech's stock price to reach $24.33 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price.
View analysts' price targets for Vaccitech or view top-rated stocks among Wall Street analysts.

Who are Vaccitech's key executives?

Vaccitech's management team includes the following people:

• Mr. William J. Enright, CEO & Board Director (Age 58, Pay $572.88k)
• Prof. Sarah Gilbert, Co-Founder
• Prof. Adrian Hill, Co-Founder & Scientific Advisor
• Mr. Georgy Egorov, Chief Financial Officer
• Dr. Margaret Marshall M.D., Chief Medical Officer
• Mr. Chris Ellis, Chief Operating Officer
• Dr. Thomas George Evans, Chief Scientific Officer
• Mr. Graham Griffiths, Chief Bus. Officer (LinkedIn Profile)
• Ms. Elizabeth Eagling-Vose, Head of Clinical Operations
• Bernie McDonald, Head of IP

Who are some of Vaccitech's key competitors?

Some companies that are related to Vaccitech include Bicycle Therapeutics (BCYC), Prometheus Biosciences (RXDX), Amarin (AMRN), FibroGen (FGEN), Xenon Pharmaceuticals (XENE), Verve Therapeutics (VERV), BridgeBio Pharma (BBIO), Amneal Pharmaceuticals (AMRX), Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), Lyell Immunopharma (LYEL), Nuvation Bio (NUVB), Amphastar Pharmaceuticals (AMPH), NGM Biopharmaceuticals (NGM) and Enanta Pharmaceuticals (ENTA).
View all of VACC's competitors.

When did Vaccitech IPO?

(VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Vaccitech's stock symbol?

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

How do I buy shares of Vaccitech?

Shares of VACC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccitech's stock price today?

One share of VACC stock can currently be purchased for approximately $9.61.

How much money does Vaccitech make?

Vaccitech has a market capitalization of $335.19 million and generates $4.82 million in revenue each year.

How many employees does Vaccitech have?

Vaccitech employs 2,021 workers across the globe.

What is Vaccitech's official website?

The official website for Vaccitech is www.vaccitech.co.uk.

Where are Vaccitech's headquarters?

Vaccitech is headquartered at THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE.

How can I contact Vaccitech?

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company can be reached via email at [email protected].